Why We Chose to Launch a Crowdfunding Campaign on Spreds

Our crowdfunding campaign is live. This bold approach, which stands apart from the methods usually used in the biotech industry, has been carefully considered. Much more than simply being an immediate source of funds, this initiative aims to convey a message.

Why crowdfunding?

Our crowdfunding campaign acts as a complement to a broader fundraising round, in which €650,000 have already been invested this year. Our goal is to double (or even triple!) this amount by appealing to the crowd, a broader audience made up of experienced investors and enthusiastic individuals, smaller and larger participations, all motivated by a variety of reasons. This is where the true value of this initiative lies.

We aim to send a clear signal to the world: yes, there is interest in a treatment for Myasthenia Gravis. And yes, people are willing to invest for its success. Over time, CuraVac’s team has come to understand the various motivations that encouraged individuals and experts alike to take interest in and support our development. 

First, there are those who are directly or indirectly affected by Myasthenia Gravis: patients, their loved ones, and dog owners whose pets are living with the disease. Their voices are particularly important, as they are the people most directly concerned. A survey we conducted in 2019 among this community revealed that 99% of the 2,632 respondents wanted us to continue developing our Targeted Active Therapy for Myasthenia Gravis, 79% wanted to be able to benefit from CuraVac’s treatment as soon as it reaches the market, and a further 15% said they would consider using it a few years after its launch.

Then, there are healthcare professionals – and, through them, the wider community affected by autoimmune diseases – who believe in the revolutionary potential of our Targeted Active Immunotherapy approach. This fits into a long-term vision. Choosing to invest today means not only helping us complete the final step before market entry, but also contributing to what could become a new era in the treatment of autoimmune diseases.

Whatever their personal or professional reasons for supporting the development of our Targeted Active Therapy, their investment is welcome and valuable. Each one contributes to a shared commitment: let us keep advancing, pursue clinical trials and production, and work together to bring our treatment for Myasthenia Gravis to market.

Why Spreds?

To carry out this mission, CuraVac has chosen to collaborate with Spreds, a crowdfunding platform based in Belgium, just like us. This platform is open to all 27 EU Member States, EFTA members, and European micro-states.

With a community of more than 48,000 members, Spreds has already helped 262 projects come to life since its foundation in 2011. Each one has been preselected by Spreds’ team before becoming available on their catalogue of well-informed companies to help the investors make an informed choice. In addition to this preselection step, Spreds ensures the awareness of its members by reminding them of the terms, conditions, and risks associated with their decision. These measures help make investing more accessible to everyone, whether experienced or new to this type of investment.

These safeguards, together with Spreds’ commitment to democratizing investment, resonate with CuraVac’s vision. We believe in the power of collective intelligence. Bringing these supports together and giving those more directly affected a way to participate are among the most meaningful ways to validate the project and demonstrate the public interest it gathers.

This project is not just CuraVac’s. It also belongs to each and every one of those who wish to contribute and help advance research and development of treatments for Myasthenia Gravis and autoimmune diseases.

Discover our crowdfunding campaign on Spreds.

Please keep in mind that investing involves serious risks, including the partial or total loss of capital. Please read the Key Investment Information Sheet and risk factors and log in before investing.